Abaloparatide to help broken bones heal faster
BCCMA:Foundational Research to Act Upon and Resist Conditions unfavorable to bone (FRACTURECURB):Role of abaloparatide for fracture healing
['FUNDING_OTHER'] · VETERANS AFFAIRS MED CTR SAN FRANCISCO · NIH-11212782
This work looks at whether the bone-building drug abaloparatide can speed and strengthen healing after fractures, especially in people at risk for delayed healing.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VETERANS AFFAIRS MED CTR SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11212782 on ClinicalTrials.gov |
What this research studies
If you have a broken bone, this project aims to understand how the bone-building drug abaloparatide might speed and strengthen healing by using lab and animal models that mimic conditions common in Veterans. Researchers will study the three different ways bone grows back inside the fracture callus and will use imaging and molecular tests to track new bone formation. They will examine signaling pathways such as IGF1 and ephrinB2/EphB4 that may be required for parathyroid-hormone–type drugs to work. The knowledge gained is intended to guide future patient treatments for fractures that heal slowly or not at all.
Who could benefit from this research
Good fit: Ideal candidates are people with fractures who are at high risk for delayed healing or non-union, such as older adults or Veterans with conditions that weaken bone.
Not a fit: People without fractures or whose fractures are already healing normally are unlikely to receive direct benefit from this research, and those with contraindications to anabolic bone drugs would not be appropriate candidates.
Why it matters
Potential benefit: If successful, this could lead to treatments that help fractures heal faster and reduce delayed or non-union complications.
How similar studies have performed: Prior work with parathyroid-hormone therapies has shown promise for speeding fracture repair, and abaloparatide is a newer, potentially stronger anabolic agent, though its actions in fracture healing are not yet well proven.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- VETERANS AFFAIRS MED CTR SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BIKLE, DANIEL DAVID — VETERANS AFFAIRS MED CTR SAN FRANCISCO
- Study coordinator: BIKLE, DANIEL DAVID
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.